Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 66Colonic Neoplasms 31Rectal Neoplasms 30Pancreatic Neoplasms 18Stomach Neoplasms 16Carcinoma, Hepatocellular 14Neoplasm Metastasis 13Esophageal Neoplasms 6Leukemia 5Neoplasms 4Lymphoma 4Liver Neoplasms 3Cholangiocarcinoma 3Carcinoma 3Adenocarcinoma Of Esophagus 3Solid Tumors 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neutropenia 2Leukemia, Biphenotypic, Acute 2Gastrointestinal Neoplasms 2Gallbladder Neoplasms 2Colorectal Cancer Metastatic 2Carcinoma, Squamous Cell 2Breast Neoplasms 2Biliary Tract Neoplasms 2Bile Duct Neoplasms 2mCRC 1Unresectable Sinonasal Tumors 1Thymoma 1Small Cell Lung Carcinoma 1

Interventions

Gemcitabine 2130-nm albumin-bound paclitaxel 2irinotecan sucrosofate 1folfirinox 1camrelizumab 1Taxes 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Borderline Resectable Pancreatic Cancer × Leucovorin × Clear all
NCT06345300 2024-04-03

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
40 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡